Ascendis Pharma A/S Revenue and Competitors
Estimated Revenue & Valuation
- Ascendis Pharma A/S's estimated annual revenue is currently $3.4M per year.
- Ascendis Pharma A/S received $115.0M in venture funding in October 2016.
- Ascendis Pharma A/S's estimated revenue per employee is $3,118
- Ascendis Pharma A/S's total funding is $85.7M.
- Ascendis Pharma A/S's current valuation is $7B. (January 2022)
Employee Data
- Ascendis Pharma A/S has 1097 Employees.
- Ascendis Pharma A/S grew their employee count by -1% last year.
Ascendis Pharma A/S's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director, Analytical Development | Reveal Email/Phone |
2 | Associate Director, Site Contracts & Budgets | Reveal Email/Phone |
3 | Director Biostatistics | Reveal Email/Phone |
4 | Director, Medical Information | Reveal Email/Phone |
5 | Senior Manager, Medical Information | Reveal Email/Phone |
6 | Regional Medical Scientist | Reveal Email/Phone |
Ascendis Pharma A/S Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7910M | 2784 | 6% | $204.3M | N/A |
#2 | $42.8M | 276 | 8% | N/A | N/A |
#3 | $3.4M | 1097 | -1% | $85.7M | N/A |
#4 | $13.2M | 12 | -77% | $263.3M | N/A |
#5 | $22.9M | 148 | 17% | N/A | N/A |
#6 | $3.6M | 23 | 10% | N/A | N/A |
#7 | $28.5M | 184 | 37% | N/A | N/A |
#8 | $1.6M | 10 | -17% | N/A | N/A |
#9 | $10.1M | 65 | 35% | N/A | N/A |
#10 | $9.1M | 59 | 59% | N/A | N/A |
What Is Ascendis Pharma A/S?
Ascendis Pharma is a biotechnology company applying its innovative prodrug technology to build a leading, fully integrated rare disease company. Our science-driven and passionate people are advancing a pipeline of endocrinology programs focused on making a difference in patients lives. By utilizing our TransCon technology with clinically validated parent drugs, we create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California, and has research and development facilities in Heidelberg, Germany, and Copenhagen, Denmark.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$85.7M
Total Funding
1097
Number of Employees
$3.4M
Revenue (est)
-1%
Employee Growth %
$7B
Valuation
N/A
Accelerator
Ascendis Pharma A/S News
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet...
Ascendis Pharma A/S (NASDAQ:ASND) Receives $184.78 Consensus PT from Analysts. Posted by admin on Apr 18th, 2022.
Ascendis Pharma also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and...
–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of ...
Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. - Completed enrollment in Phase 3 PaTHway Trial ...
Ascendis Pharma A/S Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-10-19 | $115.0M | Undisclosed | J.P. Morgan Securities LLC, | Article |